

09/762023

JC07 Rec'd PCT/PTO

01 FEB 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#6  
by  
1-26-01

Attorney Docket No.: **PENN-0749**

Inventors: **MUZYKANTOV ET AL.**

Serial No.: **NOT YET ASSIGNED**

Filing Date: **HEREWITH**

Examiner: **NOT YET ASSIGNED**

Group Art Unit: **NOT YET ASSIGNED**

Title: **TARGETING AND PROLONGING ASSOCIATION OF DRUGS TO THE LUMINAL SURFACE OF THE PULMONARY VASCULAR ENDOTHELIAL CELLS**

"Express Mail" Label No. EL722986054US  
Date of Deposit February 1, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Deborah Ehret  
Typed Name: Deborah Ehret

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

**(XX)** In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three

09/762023

JC07 Rec'd PCT/PTO 01 FEB 2001

months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- ( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
  - ( ) Certification in Accordance with §1.97(e) is set forth below; or
  - ( ) The fee of \$240.00 as set forth in §1.17(p) is attached.
- ( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- ( ) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

09/762023

RECEIVED  
01 FEB 2001

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office as the PCT Receiving Office and are referenced in the International Search Report (AA through AJ).

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Kathleen A. Tyrrell  
Registration No. 38,350

Date: February 1, 2001

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515